SIGA Technologies, Inc. (SIGA)
| Market Cap | 446.28M |
| Revenue (ttm) | 173.73M |
| Net Income (ttm) | 85.71M |
| Shares Out | 71.40M |
| EPS (ttm) | 1.20 |
| PE Ratio | 5.23 |
| Forward PE | 6.26 |
| Dividend | $0.60 (9.60%) |
| Ex-Dividend Date | n/a |
| Volume | 494,847 |
| Open | 6.21 |
| Previous Close | 6.26 |
| Day's Range | 6.03 - 6.31 |
| 52-Week Range | 4.26 - 12.83 |
| Beta | 0.89 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About SIGA
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. [Read more]
Financial Performance
In 2023, SIGA Technologies's revenue was $139.92 million, an increase of 26.31% compared to the previous year's $110.78 million. Earnings were $68.07 million, an increase of 100.76%.
Financial StatementsNews
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product,...
SIGA Technologies, Inc. (SIGA) Q3 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Diem Nguyen - CEO Dan Luckshire - CFO Conference Call Participants Jyoti Prakas...
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating SIGA Technologies, Inc. for potential violations of federal securities laws
NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating p...
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered ...
Siga Technologies to supply mpox therapy in Morocco
Drugmaker Siga Technologies said on Tuesday it would supply its therapy for mpox in Morocco, in response to a request from the country's health ministry for protection against any potential outbreak o...
SIGA Announces Agreement to Supply TPOXX® in Morocco
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SIGA Technologies...
The Law Offices of Frank R. Cruz Announces Investigation of SIGA Technologies, Inc. (SIGA) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of investors concerning the Comp...
Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating SIGA Technologies, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investig...
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced a new contract w...
Stock Of The Day: Bull Trap Snares SIGA Technologies On Heels Of Mpox Study
So-called “bull traps” often frustrate traders, as they did on Wednesday, snaring shares of SIGA Technologies Inc SIGA — and there may be another one today.
SIGA Technologies: Poised For A Potential Windfall From Monkeypox Emergency Declaration
SIGA Technologies focuses on antiviral treatments, with its lead product TPOXX (tecovirimat) approved for smallpox and other orthopoxviruses. The PALM 007 study of tecovirimat in monkeypox patients fa...
Mpox outbreak: 5 stocks to watch out for as the emergency unfolds
The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to sprea...
Topline Results from PALM 007 Study of SIGA's Tecovirimat in Treatment of Mpox Released
NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) today announced topline results from a preliminary a...
SIGA Technologies, Inc. (SIGA) Q2 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Daniel Luckshire - Chief Financial Officer ...
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference...
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
Further Advances SIGA's Strategy to Expand Access to TPOXX into More International Markets Further Advances SIGA's Strategy to Expand Access to TPOXX into More International Markets
SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript
SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Chief Financial Officer Confer...
SIGA Reports Financial Results for Three Months Ended March 31, 2024
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 3...
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference ...
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that i...
Siga Technologies: Preparing For A Contingency If Tomorrow Comes
SIGA stock is setting new 52-week highs after a strong earnings report. The post-earnings rally is also supported by a special cash dividend of $0.60, going ex-dividend on 25 March.
SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript
SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call ...